🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Singapore / NCT07791420
Starting soon Not applicable

Measurement of Acute Metabolite Changes Following Consumption of Microalgae Drinks

NCT07791420 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-09-01

Condition(s) studied

Protein Absorption and Amino Acid AvailabilityMetabolomics

Investigational drug(s) / intervention(s)

Bead-milled microalgaeNon-bead-milled microalgaeWhey protein isolateSoy protein isolateMaltodextrin (Placebo)

Bead-milled microalgae: Consume a 400 mL drink containing 20 g protein equivalent of bead-milled microalgae

Non-bead-milled microalgae: Consume a 400 mL drink containing 20 g protein equivalent of non-bead-milled microalgae

Whey protein isolate: Consume a 400 mL drink containing 20 g protein equivalent of whey protein isolate

Soy protein isolate: Consume a 400 mL drink containing 20 g protein equivalent of soy protein isolate

Maltodextrin (Placebo): Consume a 400 mL drink containing maltodextrin matched for the energy content of 20 g protein

Study summary

Protein consumption is essential for various physiological processes, with microalgae and plant proteins gaining increasing attention due to their health benefits. To better understand how different protein types and processing methods impact health outcomes, this study aims to analyse the metabolite changes in response to different protein sources.

Eligibility

Sex
ALL
Min age
21 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * English-literate and able to give informed consent * Singaporean Chinese Adults aged 21 to 60 (inclusive) * Body mass index of 18.5 to 23.0 kg/m\^2 (inclusive) * Healthy (Based on results from screening session) Exclusion Criteria: * Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention * High blood pressure (≥ 140/90 mmHg) * Underlying health conditions that may affect metabolic functions * Consuming amino acid or protein supplements, or protein drinks, regularly (i.e., more than three times a week) for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration * Weight change \> 3 kg in the past 3 months * Weight \< 50 kg * Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout) * Current smokers or have quit smoking for less than 5 years * Drinking \> 2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit) * If drinking ≤ 2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits * Not willing to stop consumption of caffeinated beverages 10 to 12 houFrs before and on the day of the test visits * Currently on a specialised diet (e.g., Halal, vegetarian, vegan, weight loss diet) * Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: seaweed or algae and their derived products, milk/dairy products (e.g., whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans * Disease or impairment of the kidney and/or liver\* * Currently diagnosed with diabetes\*, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency * Taking antibiotics 2 weeks prior to study participation * Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition * Poor peripheral venous access based on past experiences with blood drawing * Individuals with anemia and/or blood clotting disorders * Donated blood within the 12 weeks prior to study participation * Individuals with pacemaker or related electrical medical devices * Pregnant, lactating, or planning pregnancy in the next 6 months

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550 Singapore Singapore

More National University of Singapore trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07791420 on ClinicalTrials.gov ↗ ← All trials in Singapore